UPDATE: FDA panel votes against Edap's ultrasound prostate cancer ablation

An FDA advisory panel votes that French device maker Edap failed to demonstrate that its novel Ablatherm prostate cancer treatment is safe and effective.

EDAP TMS SA, Food & Drug Administration (FDA)

News Well, Pre-Market Approval (PMA), Regulatory/Compliance, Urology

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1zAOHzc